Last reviewed · How we verify
Instituto de Olhos de Goiania — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Aflibercept and ranibizumab | Aflibercept and ranibizumab | marketed | Anti-VEGF agent | VEGF-A (and VEGF-B for aflibercept) | Ophthalmology | |
| Ranibizumab and Aflibercept | Ranibizumab and Aflibercept | marketed | Anti-VEGF agent | VEGF-A (vascular endothelial growth factor-A) | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- University Hospital, Basel, Switzerland · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Instituto de Olhos de Goiania:
- Instituto de Olhos de Goiania pipeline updates — RSS
- Instituto de Olhos de Goiania pipeline updates — Atom
- Instituto de Olhos de Goiania pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Instituto de Olhos de Goiania — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-de-olhos-de-goiania. Accessed 2026-05-17.